

Annual HEP Meeting 2025

Validation and Calibration of Machine Learning Models: From Particle Identification to Eye-Disease Prognosis

Robert McNulty

r.j.mculty@liverpool.ac.uk

Supervisors:

Dr. Nikolaos Rompotis, Prof. Monica D'Onofrio,

Prof. Yalin Zheng, Dr. Philip Burgess



Introduction

- 3rd Year PhD Student under LIV.INNO CDT – joint funded with local industry partner (ARO)
 - PhD aimed at R&D projects connected to both ATLAS and ARO

Work presenting today:

- ATLAS: validation of Graph Neural Network (GNN) model for tau-lepton identification (co-developed with Dr. J. Carmignani)
- CRiA (through ARO): validation of a time-distributed Convolutional Neural Network (CNN) model for eye-disease prognosis, initially developed by Dr. J. Bridge (PhD in Health and Life Sciences)



Part I – Particle Identification


Brief Overview of τ -Leptons at ATLAS

- Leptonic decays, τ_{lep} :
 - Produces e^\pm, μ^\pm and corresponding ν 's, with BR of 35% [1]
- **Hadronic decays, τ_{had} (signal):**
 - 1 or 3 π^\pm (1- & 3-prong decays) and maybe a few π^0 , with BR of 65% [1]
 - Narrow, collimated jets with low track multiplicity
- Main **background** is quark-gluon initiated jets from QCD processes
 - Shower shape “drowns out” the narrower τ_{had} jets

Hadronic Calorimeter
Obtains π^\pm information

Electromagnetic Calorimeter
Obtains π^0 information
(via $\pi^0 \rightarrow \gamma\gamma$ and $\gamma \rightarrow e^-e^+$)

Tracking Detector
Collects charged particle track information, e.g., direction and position of π^\pm 's from τ -decay




[1] R.L. Workman *et al.* (Particle Data Group), *Prog. Theor. Exp. Phys.* **2022**, 083C01 (2022) and 2023 update

Problem and Approach - τ_{had} Identification

	τ_{had} Identification (ID) (and Decay Mode Classification)
Problem	<ul style="list-style-type: none">• τ_{had} signatures are “drowned-out” by QCD jets• Currently done via a Recurrent Neural Network (RNN) at ATLAS [ATL-PHYS-PUB-2022-044]<ul style="list-style-type: none">• RNN inputs can be used as an image input to a GNN to perform τ_{had} ID
Approach	<ul style="list-style-type: none">• To further study τ_{had} ID with a GNN based approach (TauJetGraphs):<ul style="list-style-type: none">• Requirement: to return the probability of a τ_{had} candidate originating from a τ lepton as opposed to a QCD jet

Tau ID – From RNN to GNN


Current: RNN [ATL-PHYS-PUB-2022-044]



- **RNN inputs:** track, cluster, and high-level (global) jet variables
 - Can vary in length, but must be ordered in some way (e.g., by transverse momentum, p_T)
- **GNN inputs:** Same as ID-RNN with additional π^0 variables
 - Can be unordered sets with varying lengths

N.B.: 1- and 3-prong trained separately


Proposed: TauJetGraphs, GNN



- Nodes = physics object, Layers = node label
- Nodes within a predefined distance ($\Delta R \leq 0.4$) are connected by an edge, where

$$\Delta R = \sqrt{\Delta\eta^2 + \Delta\phi^2}$$

Example Distribution: 1-prong, ΔR




Now being further developed and validated by Mehul (see his slides)

* Scores given for decay modes are summed for ID, e.g., $P(1p0n) + P(1p1n) + P(1pXn) = P(1 - \text{prong})$

Tau ID Results – RNN vs GNN

1-prong GNN Output Scores




Good signal-background separation

$$\text{Efficiency} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

$$\text{Background Rejection} = \frac{\text{False Positives} + \text{True Negatives}}{\text{False Positives}}$$

TauID GNN vs RNN ROC Curve



At 60% Efficiency

- 1-prong rejection improves in GNN by order of 10
- 3-prong rejection has some but no significant improvement


3-prong GNN shows similar performance to 1-prong GNN

	1-prong			
Efficiency	60%	75%	85%	95%
Rejection	140	62	32	12
	3-prong			
Efficiency	45%	60%	75%	95%
Rejection	280	130	64	15

Part II – Eye-Disease Prognosis

Brief Overview of Age-related Macular Degeneration

- **Macular** [[Macular Society](#)] = Small area at the centre of the retina responsible for central vision, most of our colour vision, and finer details
- Damage is **permanent**
- **Age-related Macular Degeneration (AMD)** [[NHS](#)] = Common eye disease that blurs central vision – doesn't cause complete blindness
 - Occurs when aging causes damage to the macula
 - Leading cause of vision loss in older adults (typically 50+ years)



Age-Related Eye Disease Study Dataset

- **Dataset:** Age-Related Eye Disease Study (AREDS)
 - Publicly available from: [\[NCBI\]](#)
- Each eye has up to 4 retinal images, each from a clinical visit and contains a time stamp and a marker for progression observed (signal/background)
- **Longitudinal data** – signal and background labels change over time
 - E.g., in (b) progression observed at 5 years – before this, would be considered as background (“0”)




Figure available from [\[J. Bridge, 2022, PhD Thesis\]](#)

Problem and Approach – AMD Survival Model




	Advanced AMD Progression
Problem	<ul style="list-style-type: none">• AMD progresses at different times for different people/eyes• Current approach uses a time-distributed CNN (Survival Model) [J. Bridge, 2022, PhD Thesis]<ul style="list-style-type: none">• Uses real images as inputs• Images are of the same eye (for each “event”) over time• Classification problem, but now depends on time as an input/parameter
Approach	<ul style="list-style-type: none">• To modify, extend, and finalise a Time-Distributed CNN (Survival Model)<ul style="list-style-type: none">• Requirement: to return a probability of a patient progressing by a given time, t

Survival Models – Background Information

- **Survival Models:** Estimate probability of eye progressing to advanced AMD up to a specified time
 - E.g., a **survival probability** of 0.4 is a 40% chance of **not progressing** by time, t
 - Conversely, this is a 60% chance of **progression** for time, t (**failure probability**)
- **Assumption:** Given enough time, t , all will fail (progress)

Example Baseline Hazard Functions: Exponential, Weibull, & Gompertz

Name	Equation
Baseline Hazard Function	$h_0(t)$
Hazard Function	$h(t) = h_0 e^{x\beta}$
Survival Function	$S(t) = -\exp\left\{-\int_0^t h(u) dt\right\}$
Survival Probability	$S(t) = P(T \geq t)$
Failure Probability	$F(t) = P(T < t) = 1 - S(t)$



- Weibull and Gompertz dist.'s match Exponential dist. when $\gamma = 1$ and $\gamma = 0$, respectively

Survival Models – Model Overview

- Three main stages:
 1. **Feature Extraction (via a CNN)** – results in a feature vector for each image, F_N
 2. **Mixed-Effects (ME) Layer** – accounts for missing images and times, x_i
 - a) Clinical data can then be appended to the single vector
 3. **Time-distributed CNN (Survival Model)** – estimate the Survival Function, $S(t)$
- Three models trained, each with different baseline hazards: Exponential, Weibull, and Gompertz (see previous slide)






Figure: Overview of the model architecture. Image credit: Dr. J. Bridge. Figure available from [[J. Bridge, 2022, PhD Thesis](#)]

Survival Models – Kaplan-Meier Curves

- **Kaplan-Meier (KM)** curves [\[paper\]](#) compare the distribution of survival probabilities across different populations (or data splits), and is given by:

$$S(t_j) = S(t_{j-1}) \left(1 - \frac{d_j}{n_j}\right)$$

- $S(t_j)$ and $S(t_{j-1})$ = Survival Probabilities at time t_j , and $t_j - 1$, respectively
- n_j = number of patients alive just before t_j , and d_j = number of events at t_j
- When $t = 0$, $S(0) = 1$



- Model learns the **shape parameter, β**
 - Used to fit $S(t)$
 - Predictions then compared with truth-level data from KM curves
- Predictions can be made based on patient images instead of generalised to population – important as people progress at different rates!



Survival Models – ROC Curves

With 95% Confidence Intervals

- Efficiency (TPR) = $\frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}} (\times 100\%)$
- Rejection $\left(\frac{1}{\text{FPR}}\right) = \frac{\text{False Positives} + \text{True Negatives}}{\text{False Positives}}$

	Rejection (at Efficiency)		
	0.4	0.6	0.8
Exponential	16	8	4.9
Weibull	16	9	5.8
Gompertz	14	9	5.2

	Rejection (at Efficiency)		
	0.4	0.6	0.8
Exponential	21	10	5.5
Weibull	21	10	6.5
Gompertz	19	11	5.9



- As time progresses, True Positives (TP's) increase
 - Agrees with model assumption
- Weibull maintains higher rejection at each efficiency (except for $t = 3$ Years at 0.6 efficiency)
- However, rejection is close between models at these points
 - Other metrics required for model choice decision


Survival Models - Calibration and Decision Curves

Examples

Calibration Curves

Example – Exponential Baseline Hazard


- Shows how well predicted probabilities match actual outcomes
 - ideally, predictions should align with the observed frequencies along the diagonal



Decision Curves

- Net Benefit balances TPs against FPs as a measure of the usefulness of a model, considering the relative harm of FPs

$$\text{Net Benefit} = \frac{\text{True Positives}}{n} - \frac{\text{False Positives}}{n} \left(\frac{p_t}{1-p_t} \right)$$



Summary and Next Steps

Summary:

- GNNs are useful for showing a more natural representation of particle physics data than alternatives, such as RNNs
 - Shown by improved background rejection in 1-prong Tau ID
- Despite being different fields, problems are very similar at their core (classification)
 - There is benefit in using knowledge from one field applied to another!

Next Steps:

- To develop a GNN Survival Model and compare with CNN approach
- To return to physics analysis and utilise knowledge from medical applications of machine learning

Thank you for listening
Any questions?



Backup

Hadronic Tau Decay Modes

Table: Various τ_{had} decay modes for 1- and 3-prong decays

Hadronic Decay Modes	Label	Branching Ratio, %
$\tau^{\pm} \rightarrow \pi^{\pm} \nu_{\tau}$	1p0n	(11.51 ± 0.05)
$\tau^{\pm} \rightarrow \pi^{\pm} \nu_{\tau} \pi^0$	1p1n	(29.93 ± 0.09)
$\tau^{\pm} \rightarrow \pi^{\pm} \nu_{\tau} \geq 2\pi^0$	1pXn	(10.81 ± 0.09)
$\tau^{\pm} \rightarrow \pi^{\pm} \pi^{\mp} \pi^{\pm} \nu_{\tau}$	3p0n	(9.46 ± 0.05)
$\tau^{\pm} \rightarrow \pi^{\pm} \pi^{\mp} \pi^{\pm} \nu_{\tau} \geq \pi^0$	3pXn	(5.09 ± 0.05)

Inputs used for TauID RNN, [ATL-PHYS-PUB-2019-033](#),
also used in TauJetGraphs GNN

Track inputs			Cluster inputs			High-level inputs		
Observable	1-prong	3-prong	Observable	1-prong	3-prong	Observable	1-prong	3-prong
$p_T^{\text{seed jet}}$	•	•	$p_T^{\text{jet seed}}$	•	•	$p_T^{\text{uncalibrated}}$	•	•
p_T^{track}	•	•	E_T^{cluster}	•	•	f_{cent}	•	•
$\Delta\eta^{\text{track}}$	•	•	$\Delta\eta^{\text{cluster}}$	•	•	$f_{\text{leadtrack}}^{-1}$	•	•
$\Delta\phi^{\text{track}}$	•	•	$\Delta\phi^{\text{cluster}}$	•	•	ΔR_{max}	•	•
$ d_0^{\text{track}} $	•	•	λ_{cluster}	•	•	$ S_{\text{leadtrack}} $	•	
$ z_0^{\text{track}} \sin \theta $	•	•	$\langle \lambda_{\text{cluster}}^2 \rangle$	•	•	S_T^{flight}		•
$N_{\text{IBL hits}}$	•	•	$\langle r_{\text{cluster}}^2 \rangle$	•	•	$f_{\text{track}}^{\text{iso}}$	•	•
$N_{\text{Pixel hits}}$	•	•				$f_{\text{track}}^{\text{EM}}$	•	•
$N_{\text{SCT hits}}$	•	•				$p_T^{\text{EM+track}} / p_T$	•	•
						$m^{\text{EM+track}}$	•	•
						m^{track}		•

Variable	Description
$p_T(\tau_{\text{had}})$	p_T of the τ_{had} (using calorimeter based $\tau_{\text{had-vis}}$ energy scale)
$p_T(\text{object})$	p_T of the object
$\Delta\phi(\text{object}, \tau_{\text{had}})$	Distance between the object and τ_{had} in ϕ
$\Delta\eta(\text{object}, \tau_{\text{had}})$	Distance between the object and τ_{had} in η
$\Delta\phi(\text{object}, \text{trackECal})$	Distance between the object and the extrapolation of highest- p_T τ_{had} track to EM calorimeter in ϕ
$\Delta\eta(\text{object}, \text{trackECal})$	Distance between the object and the extrapolation of highest- p_T τ_{had} track to EM calorimeter in η
$\langle\eta^1\rangle$	First moment in η in cluster shower axis
$\log(\langle r^2\rangle)$	Second moment in the radial distance of cluster cells from the shower axis
$\Delta\theta$	Distance in θ between the EM shower axis and the vector pointing from the primary vertex to the centre of the shower
$\log(\lambda_{\text{centre}})$	Distance of the cluster shower centre from the calorimeter front face measured along the shower axis
$\langle\lambda^2\rangle$	Mean distance of a cell from the shower centre along the shower axis
$\log(\langle\rho^2\rangle)$	Second moment in the cluster energy density, where $\rho = E^{\text{cluster}}/V^{\text{cluster}}$
f_{core}	Sum of energy fractions in the most energetic cells per sampling
$f_{\text{core}}^{\text{EM1}}$	Same as f_{core} but only consider EM1
$N_{\text{pos,EM1}}$	Number of cells with positive energy in EM1
$N_{\text{pos,EM2}}$	Number of cells with positive energy in EM2
E_{EM1}	Energy in the EM1 layer
E_{EM2}	Energy in the EM2 layer
$\langle\eta_{\text{EM1}}^1\rangle$ w.r.t. cluster	First moment in η in EM1 with respect to the cluster
$\langle\eta_{\text{EM2}}^1\rangle$ w.r.t. cluster	First moment in η in EM2 with respect to the cluster
$\log(\langle\eta_{\text{EM1}}^2\rangle)$ w.r.t. cluster	Second moment in η in EM1 with respect to the cluster
$\log(\langle\eta_{\text{EM2}}^2\rangle)$ w.r.t. cluster	Second moment in η in EM2 with respect to the cluster


Physics object
kinematic variables

Variables used in Decay Mode Classification
DSNN, [ATL-PHYS-PUB-2022-044](https://arxiv.org/abs/2204.044), also
utilised in TauJetGraphs GNN

Neutral pion cluster
variables

RNN – ROC Curve and Confusion Matrix

Plots taken from: [[ATL-PHYS-PUB-2022-044](#)]



Decay Mode Classification Confusion Matrix

ATLAS Simulation Preliminary
 $\sqrt{s} = 13$ TeV
 Diagonal efficiency: 81.7%
 Medium τ_{had} identification



DeepSet NN tau decay mode	1p0n	1p1n	1pXn	3p0n	3pXn
3pXn	0.0	0.6	0.7	4.2	65.1
3p0n	0.4	0.2	0.1	92.2	25.6
1pXn	0.5	6.3	59.3	0.1	2.2
1p1n	9.4	86.3	38.8	1.4	6.5
1p0n	89.6	6.6	1.1	2.0	0.6

Truth tau decay mode

TauJetGraphs – Implementing Medical Analysis Methods

N.B.: Plots made using uncalibrated model scores

- Applying calibration and decision curve analysis to TauJetGraphs can provide useful insights, e.g.,:
 - Calibration plots (left) – for 1-prong (top), model predictions reflect likelihood ratios well
 - Decision curves (right) – for the 3-prong (bottom), model shows good benefit in comparison to risks (comparing TPs to FPs w.r.t. a score threshold)
- Decision curves serve as a useful metric for comparing different models (when evaluated on the same datasets)



Age-Related Eye Disease Study Dataset

- Data is from the (publicly available) Age-Related Eye Disease Study (AREDS) dataset [\[NCBI\]](#)
- Each eye has up to four retinal images taken over time
 - Each image has a time-stamp and whether progression is observed or not
- Clinical information is also available for each patient:
 - Age (at enrolment)
 - Sex (M or F)
 - Smoked (Yes or No)
 - BMI




Figure: Example longitudinal images of AMD. Each row contains images taken from the same eye of a patient over time. The first three images in each row displays early or intermediate AMD. The fourth image for patient a) shows that the patient hasn't progressed, while for b) the patient has progressed to an advanced form of AMD. Images are from the AREDS dataset. Figure available from [\[J. Bridge, 2022, PhD Thesis\]](#)

Table: Statistical information on the portion of the AREDS dataset used in this work. Information taken from [\[J. Bridge, 2022, PhD Thesis\]](#)

	Training	Validation	Testing
Eyes	2785	1392	1392
Patients	1532	755	754
Female (%)	1528 (54.9%)	782 (56.2%)	794 (57%)
Mean Baseline Age (range)	74.4 (58.4, 87.9)	74.4 (56.9, 85.5)	74.7 (56.9, 87.8)
Mean Follow-Up Years (Range)	1.3 (0.5, 8.0)	1.3 (0.5, 12.0)	1.24 (0.5, 6.0)
Progressing (%)	476 (17.1%)	238 (17.1%)	238 (17.1%)
Mean BMI at Baseline (Range)	27.5 (8.9, 58.2)	27.4 (15.5, 54.9)	27.2 (16.1, 47.1)
Ever Smoked (%)	1499 (53.8%)	755 (55.7%)	689 (49.5%)

Age-Related Eye Disease Study Dataset

Signal Stats for Each Year, t

	Training Dataset (Signal)		Validation Dataset (Signal)		Testing Dataset (Signal)	
	Count	%	Count	%	Count	%
1 Year	317	11.4	157	11.3	192	13.8
2 Years	449	16.1	225	16.2	228	16.4
3 Years	460	16.5	232	16.7	231	16.6
Prevalence* (Total Signal)	476	17.1	238	17.1	238	17.1

*Prevalence is the rate of disease progression from the dataset:

- Event labels determined from final observation (i.e. 1 if progression observed and 0 if censored)
- Calculated as percentage of progressing eyes from total dataset

Censored Data

Table: Definitions of each type of censored data; left, right, and interval.

Type of Censoring	Definition
Left	Event already happened before patient enrolled into study
Right	Patient leaves study before event is observed
Interval	Event occurs between two observations and exact time is unclear

- AREDS Dataset contains right-censored data, meaning that there are patients who were not observed to progress to advanced forms of AMD before they left the study
- ‘Censored’ events can only be included in analysis up to the time of ‘censoring’ – i.e. they must then be ‘hidden’/removed as they provide no information past this time




Figure: Example longitudinal images of AMD. Each row contains images taken from the same eye of a patient over time. The first three images in each row displays early or intermediate AMD. The fourth image for patient a) shows that the patient hasn't progressed, while for b) the patient has progressed to an advanced form of AMD. Images are from the AREDS dataset. Figure available from [[J. Bridge, 2022, PhD Thesis](#)]

Motivations and Goals

	τ_{had} ID (TauJetGraphs)	AMD Progression (Survival Models)
Motivations	<ul style="list-style-type: none">BR for τ_{had} ($\sim 65\%$) is $\sim 2 \times$ the BR for τ_{lep} ($\sim 35\%$)ID is important across several research areas, such as:<ul style="list-style-type: none">$H \rightarrow \tau\tau$ production CERN-EP-2021-217Di-Higgs searches with $b\bar{b}\tau^+\tau^-$	<ul style="list-style-type: none">AMD is a degenerative disease – it is likely that all patients will progress to an advanced form, given enough timeThere is no cure, but treatments exist which can help slow the progression<ul style="list-style-type: none">Finding out when a patient is likely to progress is beneficial, as it allows clinicians to appropriately plan treatments and future visits
Goals	<ul style="list-style-type: none">To further study the unification of DMC & ID with a GNN:<ul style="list-style-type: none">Which should be able to handle τ_{had} candidates with 1 and 3 tracksFinal classifier should be able to classify 5 decay modes & QCD jets	<ul style="list-style-type: none">To modify, extend, and finalise a Time-Distributed CNN, referred to as a Survival Model<ul style="list-style-type: none">The model should be capable of returning a probability of a patient progressing by a given time, t

Survival Models – Mixed-Effects Layer

- Mixed-effects (ME) layer used to model spatial relationships
- The mixed-effects for the i^{th} eye is given by:

$$X_i = \begin{bmatrix} F_{1,1} & \cdots & F_{1,2049} \\ F_{2,1} & \cdots & F_{2,2049} \\ F_{3,1} & \cdots & F_{3,2049} \end{bmatrix} \begin{bmatrix} \alpha_1 \\ \vdots \\ \alpha_{2049} \end{bmatrix} + \begin{bmatrix} 1 & 0 & \frac{1}{t_0 - t_1} & \frac{1}{t_0 - t_2} \\ 1 & \frac{1}{t_1 - t_0} & 0 & \frac{1}{t_1 - t_2} \\ 1 & \frac{1}{t_2 - t_0} & \frac{1}{t_2 - t_1} & 0 \end{bmatrix} \begin{bmatrix} \beta_1 \\ \beta_2 \\ \beta_3 \\ \beta_4 \end{bmatrix} + [\epsilon_1 \quad \epsilon_2 \quad \epsilon_3]$$

Where:

- $F_1, F_2,$ and F_3 are feature vectors extracted by CNN into fixed-effects matrix
- α are fixed-effects parameters (learned by the model)
- $t_0, t_1,$ and t_2 are observation times, with t_0 being initial observation (random-effects matrix, Z)
- β are random-effects parameters (learned by the model)
- ϵ are unknown random errors
- ME layer results in a single vector, $X_i,$ with relationships between time points modelled using Z

Terms:

1. **Fixed-effects** – models the relationship within slices/images
2. **Random-effects** – models the spatial relationship between slices/images





Figure: The mixed-effects layer of the model architecture. Figure available from [[J. Bridge, 2022, PhD Thesis](#)]

Saliency Maps


Exponential Model – Progression Observed




- Here, each row is the prediction on time progression for the same eye across visits (columns)
 - I.e., A prediction is made, and the saliency map for each input image is generated – each row is a different time prediction, and each column is a clinical visit, all for the same eye
- Highlighted areas of importance remains consistent across each time prediction
 - Earlier predictions (e.g., t = 1 Year) have brighter pixels at earlier visits

Saliency Map

Exponential Model – No Progression Observed




- Earlier images contribute less than most recent images to the overall prediction
- Same cluster of pixels highlighted across each visit and for each predicted progression time
- Fewer regions highlighted than in the progressing eye




Survival Models – Kaplan-Meier Curves

Validation Dataset:




Testing Dataset:





Baseline: Exponential



Baseline: Weibull




Baseline: Gompertz




Survival Models - Output Score (Risk) Distributions





Baseline: Exponential



Baseline: Weibull



Baseline: Gompertz



Decision Curves – Background

- Net Benefit calculated using:

$$\text{Net Benefit} = \frac{\text{TP}}{n} - \left(\frac{\text{FP}}{n} \times \frac{p_t}{1 - p_t} \right)$$

Where TP = # True Positives, FP = # False Positives, n = Number of events, p_t = score threshold

An example using the figure:

- A model exists that provides a probability of a patient has a disease:
 - If near 1, model is confident they have the disease and they will ask to be treated, and similarly if it is near 0 then the model is confident that they don't have the disease and so won't ask to be treated
 - There exists a probability between 0 and 1 where the patient is unsure whether they will forgo treatment
 - This threshold probability, p_t , is where the benefit of treatment is equal to the expected benefit of avoiding treatment.
 - Solving this from the figure $\Rightarrow p_t a + (1 - p_t)b = p_t c + (1 - p_t)d$
 - Becoming: $\frac{a-c}{d-b} = \frac{1-p_t}{p_t}$, where $d-b$ is the consequence of being treated unnecessarily (harm associated with FP result), and $a-c$ is the consequence of avoiding treatment when it would have been of benefit (harm from FN result)
 - "Harm" is considered as the overall effect of negative consequences of a particular decision

For p = probability of disease, and a , b , c , and d give the value associated with each outcome in terms such as quality-adjusted life-years. Figure from [doi: [10.1177/0272989X06295361](https://doi.org/10.1177/0272989X06295361)]




Figure 1 A decision tree for treatment. The probability of disease is given by p ; a , b , c , and d give, respectively, the value of true positive, false positive, false negative, and true negative.

Metric Definitions

- **Accuracy** – The fraction of correctly classified samples (if normalised = True)
- **Purity (Precision)** – Purity is the measure of how well a classifier avoids incorrectly labelling a sample as positive. It's calculated as true positives divided by true positives plus false positives:
 - $\frac{tp}{tp+fp}$ where tp is true positive and fp is false positive
- **Efficiency (Recall)** – Efficiency measures how well a classifier finds all the true positives. It's calculated as true positives divided by true positives plus false negatives:
 - $\frac{tp}{tp+fn}$ where tp is true positive and fn is false negative
- **Background Rejection** – The inverse of the Background Selection Efficiency, depending on the Signal Selection Efficiency

Glossary

- **AMD** – Age-related Macular Degeneration
- **AREDS** – Age-Related Eye Disease Study
- **ID** – Identification
- **DMC** – Decay Mode Classification
- τ_{had} - Hadronically decaying τ -lepton
- **RNN** – Recurrent Neural Network
- **DSNN** - DeepSet Neural Network
- **GNN** – Graph Neural Network
- **CNN** – Convolutional Neural Network
- **ROC Curve** - Receiver Operator Characteristic Curve